Gara Jalqabaatti › Leukemia Myeloidii Hamaa › New York › Buffalo
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Buffalo, NY keessatti
Qorannoo 19 Leukemia Myeloidii Hamaa f Buffalo fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Roswell Park Cancer Institute, Buffalo
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Roswell Park Cancer Institute, Buffalo
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Roswell Park Cancer Institute, Buffalo
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- Roswell Park Comprehensive Cancer Center, Buffalo
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Roswell Park Cancer Institute, Buffalo
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Roswell Park Cancer Institute, Buffalo
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Roswell Park Cancer Institute, Buffalo
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Roswell Park Cancer Institute, Buffalo
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Roswell Park Cancer Institute, Buffalo
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 1/2
- Roswell Park Comprehensive Cancer Center, Buffalo
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Namoota walitti qabaa jiraSadarkaa 3
- State University of New York at Buffalo, Buffalo
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Roswell Park Comprehensive Cancer Center, Buffalo
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Namoota walitti qabaa jiraSadarkaa 2
- Roswell Park Cancer Institute, Buffalo
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Roswell Park Cancer Institute, Buffalo
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- Roswell Park Comprehensive Cancer Center, Buffalo
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Roswell Park Comprehensive Cancer Center, Buffalo
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Namoota walitti qabaa jiraSadarkaa 1
- Roswell Park Comprehensive Cancer Center, Buffalo
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Namoota walitti qabaa jiraSadarkaa 1
- Roswell Park Cancer Institute, Buffalo
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1
- Roswell Park Cancer Institute, Buffalo
Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti
- Houston, TXQorannoo 85
- New York City, NYQorannoo 51
- Boston, MAQorannoo 44
- Seattle, WAQorannoo 41
- Baldwin Park, CAQorannoo 40
- Columbus, OHQorannoo 35
- Philadelphia, PAQorannoo 34
- Durham, NCQorannoo 33
- Atlanta, GAQorannoo 31
- Tampa, FLQorannoo 29
- Chicago, ILQorannoo 26
- Portland, ORQorannoo 25
Qorannoo biroo Buffalo keessatti
- Kansara Qara'a Non-Small CellQorannoo 19
- Saree (Gosoota Hunda)Qorannoo 19
- Dhibee QaraQorannoo 16
- Saree OljooQorannoo 16
- Kansarii OvariiQorannoo 13
- Kansara MetastatikiiQorannoo 11
- Kansarii ProstateQorannoo 11
- MelanomaQorannoo 10
- Myeloma Baay’eeQorannoo 10
- ObesityQorannoo 9
- Burkitt LymphomaQorannoo 8
- Myelodysplastic SyndromesQorannoo 8
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.